CHARACTERIZATION OF THE INVIVO BEHAVIOR OF A CONTROLLED-RELEASE FORMULATION OF LEVODOPA (SINEMET CR)

被引:42
|
作者
WILDING, IR
HARDY, JG
DAVIS, SS
MELIA, CD
EVANS, DF
SHORT, AH
SPARROW, RA
YEH, KC
机构
[1] UNIV NOTTINGHAM,SCH PHARM,DEPT PHARMACEUT SCI,NOTTINGHAM NG7 2RD,ENGLAND
[2] QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND
[3] MERCK SHARP & DOHME LTD,W POINT,PA 19486
关键词
SINEMET CR; LEVODOPA; CARBIDOPA; GAMMA-SCINTIGRAPHY; GASTROINTESTINAL TRANSIT; ABSORPTION;
D O I
10.1097/00002826-199108000-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The gastrointestinal transit and systemic absorption of Sinement CR(50-200) controlled-release tablets and standard Sinemet (25-100) immediate-release (IR) tablets have been studied in fasted and fed healthy human subjects. Both formulations were labelled with a gamma-emitting radionuclide and their gastric emptying, colon arrival and in vivo disintegration profiles monitored using gamma scintigraphy. The IR dosage forms were found to disperse soon after administration and to empty rapidly from both fasted and fed stomachs. Erosion of the CR system was independent of food or stomach pH. The CR tablet was observed to disintegrate fully in the gastrointestinal (GI) tract, resulting in complete release of levodopa over a 3-4 h time period. Considerable intersubject variation was found to exist for levodopa absorption. Absorption was more protracted with Sinemet CR than with standard Sinemet, due to the controlled release characteristics of the tablet matrix. There was no rapid initial absorption phase and instead, a gradual build-up in the absorption profile occurred.
引用
收藏
页码:305 / 321
页数:17
相关论文
共 50 条
  • [41] PHARMACOKINETICS OF SARPOGRELATE HYDROCHLORIDE CONTROLLED-RELEASE FORMULATION IN COMPARISON TO IMMEDIATE-RELEASE FORMULATION, AND INFLUENCE OF FOOD ON THE PHARMACOKINETICS OF SARPOGRELATE HYDROCHLORIDE CONTROLLED-RELEASE FORMULATION.
    Kim, T.
    Kim, J.
    Jung, J.
    Lee, S.
    Ko, J.
    Huh, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S72 - S72
  • [42] Oral controlled-release formulation in veterinary medicine
    Lavy, Eran
    Steinman, Amir
    Soback, Stefan
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2006, 23 (03): : 165 - 204
  • [43] CONTROLLED-RELEASE SINEMET (CR-4) - A DOUBLE-BLIND CROSSOVER STUDY IN PATIENTS WITH FLUCTUATING PARKINSONS-DISEASE
    AHLSKOG, JE
    MUENTER, MD
    MCMANIS, PG
    BELL, GN
    BAILEY, PA
    MAYO CLINIC PROCEEDINGS, 1988, 63 (09) : 876 - 886
  • [44] CLINICAL AND BIOCHEMICAL-STUDIES WITH CONTROLLED-RELEASE LEVODOPA CARBIDOPA
    NUTT, JG
    WOODWARD, WR
    CARTER, JH
    NEUROLOGY, 1986, 36 (09) : 1206 - 1211
  • [45] Influence of controlled-release levodopa on quality of sleep and nocturnal movements
    Schaeffer, E.
    Zaunbrecher, L.
    Liepelt-Scarfone, I.
    Hansen, C.
    Maetzler, W.
    Nussbaum, S.
    Roeben, B.
    Elshehabi, M.
    Saraykin, P.
    Otterbein, S.
    Busch, J.
    Berg, D.
    MOVEMENT DISORDERS, 2019, 34 : S661 - S661
  • [46] RELEASE OF CYANATRYN FROM A CONTROLLED-RELEASE FORMULATION INTO FLOWING WATER
    OSGERBY, JM
    PESTICIDE SCIENCE, 1975, 6 (06): : 675 - 685
  • [47] INVIVO EVALUATION OF CHOLESTEROL AS A MATRIX FOR CONTROLLED-RELEASE OF PROGESTERONE
    BECK, LR
    LOWRY, SL
    CONTRACEPTION, 1978, 18 (05) : 497 - 505
  • [48] Formulation and pharmacokinetic studies of acyclovir controlled-release capsules
    Tu, JS
    Wang, LB
    Yang, J
    Fei, H
    Li, XM
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (07) : 687 - 692
  • [49] Development of Controlled-Release Formulation to Improve Bioavailability of Esomeprazole
    Soujanya, C.
    Satya, B. Lakshmi
    Marepally, Chandrika
    Vinjamuri, Bhavya Sri
    Ettadi, Rupika Reddy
    ASIAN JOURNAL OF PHARMACEUTICS, 2022, 16 (04) : 471 - 477
  • [50] Design of controlled-release formulation for ivermectin using silicone
    Maeda, H
    Brandon, M
    Sano, A
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 261 (1-2) : 9 - 19